Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 183750 and Irinotecan in Refractory Colorectal Cancer
NCT01675128Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Dec 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of LY2275796 in colorectal cancer (CRC), solid tumor, sponsored by National Cancer Institute. Started Aug 2012; status: completed.
02
Drugs
LY2275796
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT01675128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01675128.